ArticleFrontiers in immunology2021
Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Systematic review and network meta-analysis of performance of the Sapporo criteria, the revised Sapporo criteria, and the 2023 ACR/EULAR APS classification criteria for patients with antiphospholipid syndrome.Frontiers in immunology · 2026Pooled it
- Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review.Frontiers in immunology · 2024Pooled it
- Prognostic value of antiphospholipid antibodies in pregnancy outcomes in systemic lupus erythematosus.RMD open · 2026Article
- Comparison Between Chemiluminescent Assay and Enzyme-Linked ImmunoSorbent Assay Techniques for the Detection of Anti-Cardiolipin and Anti-β2 Glycoprotein I Antibody Values.Diagnostics (Basel, Switzerland) · 2026Article
- A review of the impact of isolated antiphospholipid antibody positivity on pregnancy outcomes and clinical management strategies.Frontiers in immunology · 2026Review
- Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.BMC medicine · 2025Article
- Exploring the impact of acute viral exposure on clinical characteristics and antibody profiles in antiphospholipid syndrome: a study in CAPSTONE.Clinical and experimental medicine · 2024Article
- Antiphospholipid antibodies in patients with antiphospholipid syndrome.Biochemia medica · 2024Review
- Proteomics analysis of plasm exosomes in early pregnancy among normal pregnant women and those with antiphospholipid syndrome.Heliyon · 2024Article
- Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome.Rheumatology and therapy · 2023Article
- Tacrolimus shows adequate efficacy in patients with antiphospholipid antibodies associated thrombocytopenia: a retrospective cohort study.Clinical and experimental medicine · 2023Article
- Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China.Lupus science & medicine · 2023Article
- Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort.RMD open · 2023Article
- Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis.Biomedicines · 2023Article
- Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis.Frontiers in immunology · 2023Article
- Sex Differences in Clinical Characteristics and Prognosis in Primary Thrombotic Antiphospholipid Syndrome.Frontiers in cardiovascular medicine · 2022Article
- Comparison of different assays for the detection of anticyclic citrullinated peptide antibodies in patients with rheumatoid arthritis.Frontiers in immunology · 2022Article
- Diagnosis of Antiphospholipid Syndrome by Chemiluminescent or Enzyme-Linked Immunosorbent Assay - A Comparison Study and Comprehensive Literature Review.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diagnosis of antiphospholipid syndrome (APS) is based on the positivity of laboratory criteria antiphospholipid antibodies (aPLs). Test results for aPLs could be contradictory among different detection methods as well as commercial manufacturers. This study aimed to assess and compare the diagnostic and analytic performances of four commercial assays prevalently used in China. Methods: A total of 313 patients including 100 patients diagnosed with primary APS, 52 with APS secondary to SLE, 71 with SLE, and 90 health controls were recruited. Serum IgG, IgM, and IgA for aCL, and a Results: CLIA by YHLO Biotech Co. was considered as the system with the best predictive power, where 58.55 and 57.89% of APS patients were positive for aCL or a Conclusion: CLIA was considered as a better platform for aPL detection in APS diagnosis. A combination of other detection platforms could assist in differential diagnosis as well as in identifying high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.